[{"orgOrder":0,"company":"Kolinpharma","sponsor":"Nemysis","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Iron Hydroxide Adipate Tartrate","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Kolinpharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kolinpharma \/ Nemysis","highestDevelopmentStatusID":"12","companyTruncated":"Kolinpharma \/ Nemysis"}]

Find Clinical Drug Pipeline Developments & Deals by Kolinpharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Kolinpharma will market Iron Hydroxide Adipate Tartrate (IHAT), an oral iron supplement for iron deficiency, utilizing its existing sales network under the brand KIPFeR.

                          Brand Name : KIPFeR

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          January 10, 2024

                          Lead Product(s) : Iron Hydroxide Adipate Tartrate

                          Therapeutic Area : Hematology

                          Highest Development Status : Approved

                          Sponsor : Nemysis

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank